主页文献库搜索
A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-flu...

Riess(H),Helm(A),Niedergethmann(M),Schmidt... J Clin Oncol 0000-00-00

...mOS). Study was powered to detect a significant difference with 80% probability at a significance level of 0,05 when 392...

Temozolomide and intravenous irinotecan for refractory Ewing's sarcoma: A ret...

Wagner(L M),McAllister(N),Rausen(A),McCarv... J Clin Oncol 0000-00-00

...mos (range 5-13) after completion. All but four received from 1-5 prior treatment regimens, and 8 patients received prio...

Outcome for children ≤3 years of age with malignant brain or spinal cord tumo...

Thorarinsdottir(H K),Rood(B),Lafond(D),Per... J Clin Oncol 0000-00-00

...mos; 2 had received post-HDC radiation. 8 patients are alive and disease free 8 to 70 mos after completion of HDC (media...

Significance of elevated serum lactate dehydrogenase (LDH) in patients underg...

Kojouri(K),Pant(S),Kamble(R),Sylvester-Koh... J Clin Oncol 0000-00-00

...mos (median: 25 mos) after transpl, and 7 pts (14%) are alive at time of analysis, 7-75 mos (median: 40 mos) after trans...

Treatment of Burkitt lymphoma: A single institution's experience.

Patel(T),Drazin(N),Nguyen(A),Hool(H),Agaja... J Clin Oncol 0000-00-00

...mos.), and one was successfully salvaged with McM with rituximab (McM+R) (NED at 51 months). One pt. treated with EPOCH+...

Pharmacokinetic (PK) and clinical phase II trial of imatinib in patients with...

Eckel(F),von Delius(S),Dobritz(M),Fend(F),... J Clin Oncol 0000-00-00

...mos and 3.7 mos in pts with SD. In pts treated with 400 mg imatinib there were no significant differences in PKs (t 22.0...

Cetuximab with oxaliplatin and capecitabine (CAPOX)in patients with metastati...

Grothe(W),Arnold(D),Peinert(S),Voigt(W),Ma... J Clin Oncol 0000-00-00

...mos (0.25+-9.6), median overall survival is 5.5+ mos (0.6-10.9+) (7 pts ongoing).,Combination of Cetuximab plus CAPOX ha...

Pilot study of celecoxib in oral premalignant lesions (OPLs): Preliminary res...

Wirth(L J),Moran(A E),Krane(J F),Weeks(L),... J Clin Oncol 0000-00-00

...mos, when biopsies were repeated.,18 patients are evaluable at 3 mos, 10 at 12 mos. One patient was withdrawn for gr 2 a...

Outcome of patients with advanced non-small-cell lung cancer and ECOG perform...

Gebbia(V),Galetta(D),Lorusso(V),Colucci(G)... J Clin Oncol 0000-00-00

...mos (1-13.5 mos) with a 6-month progression-free probability rate of 43%. This difference in median TTP was highly signi...

Multi-drug chemotherapy for pancreatic cancer.

Bruckner(H W),Myo(M),Zaw(K),Filipova(O),He... J Clin Oncol 0000-00-00

...mos on adding 80 mg/M of Irinotecan to a 'failed' q2 wk Gemzar-Fluorouracil-Cisplatin regimen (The Oncologist 6:488 2001...

上一页 687 688 689 690 691 692 693 694 695 下一页 691 / 共 704

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: [email protected]